The 36-month beta value for BCRX is at 1.94. Analysts have varying views on the stock, with 5 analysts rating it as a “buy,” 2 rating it as “overweight,” 2 as “hold,” and 1 as “sell.”
The public float for BCRX is 198.56M, and currently, shorts hold a 15.38% of that float. The average trading volume for BCRX on April 10, 2024 was 3.18M shares.
BCRX) stock’s latest price update
Biocryst Pharmaceuticals Inc. (NASDAQ: BCRX)’s stock price has increased by 4.12 compared to its previous closing price of 4.61. However, the company has seen a 2.35% increase in its stock price over the last five trading sessions. GlobeNewsWire reported 2024-03-25 that RESEARCH TRIANGLE PARK, N.C., March 25, 2024 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 28, 2024, at 2:30 p.m. ET and the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, at 10:15 a.m. ET.
BCRX’s Market Performance
Biocryst Pharmaceuticals Inc. (BCRX) has seen a 2.35% rise in stock performance for the week, with a -11.60% decline in the past month and a -37.25% plunge in the past quarter. The volatility ratio for the week is 4.58%, and the volatility levels for the past 30 days are at 5.49% for BCRX. The simple moving average for the past 20 days is -4.31% for BCRX’s stock, with a -22.47% simple moving average for the past 200 days.
Analysts’ Opinion of BCRX
Many brokerage firms have already submitted their reports for BCRX stocks, with JP Morgan repeating the rating for BCRX by listing it as a “Overweight.” The predicted price for BCRX in the upcoming period, according to JP Morgan is $10 based on the research report published on November 20, 2023 of the previous year 2023.
RBC Capital Mkts, on the other hand, stated in their research note that they expect to see BCRX reach a price target of $10, previously predicting the price at $9. The rating they have provided for BCRX stocks is “Outperform” according to the report published on September 18th, 2023.
Jefferies gave a rating of “Buy” to BCRX, setting the target price at $11 in the report published on August 04th of the previous year.
BCRX Trading at -9.93% from the 50-Day Moving Average
After a stumble in the market that brought BCRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -47.05% of loss for the given period.
Volatility was left at 5.49%, however, over the last 30 days, the volatility rate increased by 4.58%, as shares sank -9.77% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -11.76% lower at present.
During the last 5 trading sessions, BCRX rose by +2.35%, which changed the moving average for the period of 200-days by -31.43% in comparison to the 20-day moving average, which settled at $4.99. In addition, Biocryst Pharmaceuticals Inc. saw -19.87% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BCRX starting from SANDERS MACHELLE, who sale 4,000 shares at the price of $7.98 back on Jun 15 ’23. After this action, SANDERS MACHELLE now owns 25,611 shares of Biocryst Pharmaceuticals Inc., valued at $31,920 using the latest closing price.
Hutson Nancy J, the Director of Biocryst Pharmaceuticals Inc., sale 12,866 shares at $8.04 during a trade that took place back on Jun 14 ’23, which means that Hutson Nancy J is holding 81,818 shares at $103,443 based on the most recent closing price.
Stock Fundamentals for BCRX
Current profitability levels for the company are sitting at:
- -0.31 for the present operating margin
- 0.98 for the gross margin
The net margin for Biocryst Pharmaceuticals Inc. stands at -0.68. The total capital return value is set at -0.28.
Based on Biocryst Pharmaceuticals Inc. (BCRX), the company’s capital structure generated 2.19 points at debt to capital in total, while cash flow to debt ratio is standing at -0.11. The debt to equity ratio resting at -1.84. The interest coverage ratio of the stock is -0.96.
Currently, EBITDA for the company is -102.05 million with net debt to EBITDA at -8.01. When we switch over and look at the enterprise to sales, we see a ratio of 5.21. The receivables turnover for the company is 5.82for trailing twelve months and the total asset turnover is 0.64. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.31.
Conclusion
In conclusion, Biocryst Pharmaceuticals Inc. (BCRX) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
